| Display title | Chemistry:Surinabant |
| Default sort key | Surinabant |
| Page length (in bytes) | 6,941 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 803239 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>OrgMain |
| Date of page creation | 21:33, 5 February 2024 |
| Latest editor | imported>OrgMain |
| Date of latest edit | 21:33, 5 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Surinabant (SR147778) is a cannabinoid receptor type 1 antagonist developed by Sanofi-Aventis. It is being investigated as a potential treatment for nicotine addiction, to assist smoking cessation. It may also be developed as an anorectic drug to assist with weight loss, however there are already several... |
